ReviewCurrent opinion in pulmonary medicine2026
Oxygen therapy in interstitial lung disease - navigating benefit and burden.
Review in Current opinion in pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOxygen therapy is a key component of interstitial lung disease (ILD) management. This review summarizes the current evidence and explores how to balance its benefits and burdens in people with ILD. RECENT
findingsHypoxemia frequently occurs in ILD and is associated with worse prognosis, but the extent to which oxygen therapy modifies outcomes remains uncertain. Observational findings suggest home oxygen therapy may reduce acute exacerbations and hospitalizations in people with ILD with a life-expectancy of more than 1 year. Ambulatory oxygen can improve symptoms and health-related quality of life in some patients; however, recent evidence indicates that portable oxygen concentrators may not improve daily oxygenation, symptoms, or physical activity. In patients with isolated exertional or nocturnal desaturation or significant respiratory symptoms with hypoxemia, careful consideration of individual benefit versus burden is essential within a shared decision-making framework. High-flow oxygen therapy is effective for acute respiratory failure, but its role in palliative care, pulmonary rehabilitation, and especially in the home environment, are areas of ongoing investigation. SUMMARY: Oxygen therapy can support symptom relief in ILD, but its impact on long-term outcomes is unclear. High-quality evidence remains sparse, and advances in oxygen delivery technologies are needed to improve effectiveness while minimizing burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.